COUR Pharmaceutical Development Company
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, COUR Pharmaceutical Development Company sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
COUR Pharmaceutical Development Company: 5 sponsored US clinical trials, 2 recruiting.
COUR Pharmaceutical Development Company sponsors 5 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is MuSK MG, with 1 trials.
Upper-quartile sponsor footprint
COUR Pharmaceutical Development Company sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
5 total, page 1 of 1
CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)
NCT06783309
Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis
NCT06106672
CNP-201 in Subjects With Peanut Allergy
NCT05250856
Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis
NCT05104853
Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-201 in Subjects Ages 16-35 With Peanut Allergy
NCT04950504
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
What is open in the COUR Pharmaceutical Development Company pipeline
2 recruiting of 5 indexed (40% open); 1 completed (20%).
Phase mix: 0 late (III/IV) vs 5 early (I/II) (early-phase heavy).
Top condition: MuSK MG (1 trial), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
COUR Pharmaceutical Development Company: open-pipeline peers nationwide
Peers matched on 5 registered trials and 40% open enrollment, not the therapeutic-area sidebar.
COUR Pharmaceutical Development Company sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 trials (± recruiting share)
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors near 40% open enrollment (± trial volume)
- Ad scientiam · 40% recruiting · 5 trials
- Alto Neuroscience · 40% recruiting · 10 trials
- Bonafide Health · 40% recruiting · 5 trials
- Brooks Rehabilitation · 40% recruiting · 5 trials
Related
What to do with this COUR Pharmaceutical Development Company page
5 registered trials is a research-attention snapshot, not an endorsement of COUR Pharmaceutical Development Company or any single study.
- 2 of COUR Pharmaceutical Development Company's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- MuSK MG is the condition COUR Pharmaceutical Development Company studies most, compare against other sponsors active in the same condition before evaluating a specific study. See MuSK MG trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
COUR Pharmaceutical Development Company pipeline card: 5 registered trials from official public datasets.Report a data error.